Patient volume slows for sleep, oxygen, report finds
By HME News Staff
Updated 10:52 AM CDT, Mon October 28, 2024
NEW YORK – Respondents to Needham’s latest Sleep and Oxygen Survey report they saw slower sleep patient volume growth in the last 12 months, and they expect that to continue for the next 12 months. They report they have seen virtually no impact on their sleep patient volume from GLP-1 drugs. They also report ResMed will hold flow generator share but lose mask share over the next 12 months. For oxygen, respondents saw slower oxygen patient volume growth in the last 12 months, and they expect slower growth in the next 12 months. They gave Inogen’s Rove 6 portable oxygen concentrator the highest rating and report the company will gain share over the next 12 months. Overall, Needham believes the results of the survey are mixed for ResMed’s domestic sleep business and positive for Inogen’s domestic B2B business.
Comments